ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Renal resistive index for risk stratification and functional evaluation after transcatheter mitral valve repair: the ReRISE study.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe renal resistive index (RRI) is increasingly used as a non-invasive marker of cardiorenal interaction. We aimed to determine (i) whether baseline RRI predicts survival after mitral transcatheter edge-to-edge repair (M-TEER) and (ii) whether RRI changes in response to the procedure.
methodsIn this prospective, single-center cohort we enrolled consecutive patients with severe mitral regurgitation who underwent M-TEER between October 2020 and December 2021 (trial registration number 412/20, date of registration 02.09.2020). Baseline demographics, estimated laboratory parameters, comprehensive echocardiography, and Doppler-derived RRI were collected before and 3 months after intervention. The primary endpoint was all-cause mortality. Associations were analyzed with multivariable Cox regression. Renal endpoints were not systematically collected and were therefore not included as clinical outcome measures.
resultsAmong 109 patients (53.2% women), the median baseline RRI was 0.71 (IQR 0.67-0.75) and showed no correlation with eGFR, left-ventricular ejection fraction, or echocardiographic measurements of mitral regurgitation at baseline. Higher RRI was associated with all-cause mortality, and in exploratory post hoc analyses an RRI cutoff > 0.70 remained predictive independent of baseline renal function (HR 5.37, p 0.07). RRI improved significantly 3 months after M-TEER (0.67; IQR 0.63-0.70; p < 0.001), particularly in patients with a post-procedural MR reduction of at least 1 grade. However, the change in RRI showed no correlation with mortality or changes in renal function.
conclusionsA baseline RRI above 0.70 was independently associated with mortality following M-TEER, underscoring its potential prognostic relevance. The marked post-procedural decline in RRI, especially in patients with relevant MR improvement, suggests that RRI reflects hemodynamic rather than renal filtration changes. Given the limited sample size and number of events, these findings should be considered exploratory and hypothesis-generating, requiring validation in larger multicenter cohorts.
Indexed as
Identifiers
41504913What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.